{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T02:26:33Z","timestamp":1788143193406,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T00:00:00Z","timestamp":1645660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T00:00:00Z","timestamp":1645660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s00467-022-05484-7","type":"journal-article","created":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T19:02:42Z","timestamp":1645729362000},"page":"2667-2677","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Real-world effectiveness of burosumab in children with X-linked hypophosphatemic rickets"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4945-9480","authenticated-orcid":false,"given":"Neil J.","family":"Paloian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blaise","family":"Nemeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Sharafinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Modaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,24]]},"reference":[{"key":"5484_CR1","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s00247-012-2532-x","volume":"43","author":"RM Shore","year":"2012","unstructured":"Shore RM, Chesney RW (2012) Rickets: part I. Pediatr Radiol 43:140\u2013151","journal-title":"Pediatr Radiol"},{"key":"5484_CR2","doi-asserted-by":"publisher","first-page":"17101","DOI":"10.1038\/nrdp.2017.101","volume":"3","author":"TO Carpenter","year":"2017","unstructured":"Carpenter TO, Shaw NJ, Portale AA, Ward LM, Abrams SA, Pettifor JM (2017) Rickets. Nat Rev Dis Primers 3:17101","journal-title":"Nat Rev Dis Primers"},{"key":"5484_CR3","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/jbmr.340","volume":"26","author":"TO Carpenter","year":"2011","unstructured":"Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL (2011) A clinician\u2019s guide to X-linked hypophosphatemia. J Bone Miner Res 26:1381\u20131388","journal-title":"J Bone Miner Res"},{"key":"5484_CR4","doi-asserted-by":"crossref","unstructured":"(1995) A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat Genet 11:130\u2013136","DOI":"10.1038\/ng1095-130"},{"key":"5484_CR5","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1002\/jbmr.3992","volume":"35","author":"AL Lecoq","year":"2020","unstructured":"Lecoq AL, Chaumet-Riffaud P, Blanchard A, Dupeux M, Rothenbuhler A, Lambert B, Durand E, Boros E, Briot K, Silve C, Francou B, Piketty M, Chanson P, Brailly-Tabard S, Linglart A, Kamenicky P (2020) Hyperparathyroidism in patients with X-linked hypophosphatemia. J Bone Miner Res 35:1263\u20131273","journal-title":"J Bone Miner Res"},{"key":"5484_CR6","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1056\/NEJM199112263252604","volume":"325","author":"CF Verge","year":"1991","unstructured":"Verge CF, Lam A, Simpson JM, Cowell CT, Howard NJ, Silink M (1991) Effects of therapy in X-linked hypophosphatemic rickets. N Engl J Med 325:1843\u20131848","journal-title":"N Engl J Med"},{"key":"5484_CR7","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s40265-018-0905-7","volume":"78","author":"YN Lamb","year":"2018","unstructured":"Lamb YN (2018) Burosumab: first global approval. Drugs 78:707\u2013714","journal-title":"Drugs"},{"key":"5484_CR8","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","volume":"393","author":"EA Imel","year":"2019","unstructured":"Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O, Simmons JH, Padidela R, Namba N, Cheong HI, Pitukcheewanont P, Sochett E, H\u00f6gler W, Muroya K, Tanaka H, Gottesman GS, Biggin A, Perwad F, Mao M, Chen C-Y, Skrinar A, San Martin J, Portale AA (2019) Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet 393:2416\u20132427","journal-title":"Lancet"},{"key":"5484_CR9","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","volume":"378","author":"TO Carpenter","year":"2018","unstructured":"Carpenter TO, Whyte MP, Imel EA, Boot AM, Hogler W, Linglart A, Padidela R, Van\u2019t Hoff W, Mao M, Chen CY, Skrinar A, Kakkis E, San Martin J, Portale AA (2018) Burosumab therapy in children with X-linked hypophosphatemia. N Engl J Med 378:1987\u20131998","journal-title":"N Engl J Med"},{"key":"5484_CR10","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S2213-8587(18)30338-3","volume":"7","author":"MP Whyte","year":"2019","unstructured":"Whyte MP, Carpenter TO, Gottesman GS, Mao M, Skrinar A, San Martin J, Imel EA (2019) Efficacy and safety of burosumab in children aged 1\u20134 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial. Lancet Diabetes Endocrinol 7:189\u2013199","journal-title":"Lancet Diabetes Endocrinol"},{"key":"5484_CR11","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","volume":"15","author":"D Haffner","year":"2019","unstructured":"Haffner D, Emma F, Eastwood DM, Duplan MB, Bacchetta J, Schnabel D, Wicart P, Bockenhauer D, Santos F, Levtchenko E, Harvengt P, Kirchhoff M, Di Rocco F, Chaussain C, Brandi ML, Savendahl L, Briot K, Kamenicky P, Rejnmark L, Linglart A (2019) Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol 15:435\u2013455","journal-title":"Nat Rev Nephrol"},{"key":"5484_CR12","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1177\/000456329803500203","volume":"35","author":"RB Payne","year":"1998","unstructured":"Payne RB (1998) Renal tubular reabsorption of phosphate (TmP\/GFR): indications and interpretation. Ann Clin Biochem 35:201\u2013206","journal-title":"Ann Clin Biochem"},{"key":"5484_CR13","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1373\/clinchem.2011.177741","volume":"58","author":"DA Colantonio","year":"2012","unstructured":"Colantonio DA, Kyriakopoulou L, Chan MK, Daly CH, Brinc D, Venner AA, Pasic MD, Armbruster D, Adeli K (2012) Closing the gaps in pediatric laboratory reference intervals: a CALIPER database of 40 biochemical markers in a healthy and multiethnic population of children. Clin Chem 58:854\u2013868","journal-title":"Clin Chem"},{"key":"5484_CR14","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/tropej\/46.3.132","volume":"46","author":"TD Thacher","year":"2000","unstructured":"Thacher TD, Fischer PR, Pettifor JM, Lawson JO, Manaster BJ, Reading JC (2000) Radiographic scoring method for the assessment of the severity of nutritional rickets. J Trop Pediatr 46:132\u2013139","journal-title":"J Trop Pediatr"},{"key":"5484_CR15","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.bone.2019.02.010","volume":"122","author":"TD Thacher","year":"2019","unstructured":"Thacher TD, Pettifor JM, Tebben PJ, Creo AL, Skrinar A, Mao M, Chen CY, Chang T, San Martin J, Carpenter TO (2019) Rickets severity predicts clinical outcomes in children with X-linked hypophosphatemia: utility of the radiographic Rickets Severity Score. Bone 122:76\u201381","journal-title":"Bone"},{"key":"5484_CR16","first-page":"1","volume":"11","author":"RJ Kuczmarski","year":"2002","unstructured":"Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z, Wei R, Curtin LR, Roche AF, Johnson CL (2002) 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 11:1\u2013190","journal-title":"Vital Health Stat"},{"key":"5484_CR17","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","volume":"375","author":"RE Sherman","year":"2016","unstructured":"Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, LaVange L, Marinac-Dabic D, Marks PW, Robb MA, Shuren J, Temple R, Woodcock J, Yue LQ, Califf RM (2016) Real-world evidence - what is it and what can it tell us? N Engl J Med 375:2293\u20132297","journal-title":"N Engl J Med"},{"key":"5484_CR18","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/bjc.2013.725","volume":"110","author":"CM Booth","year":"2014","unstructured":"Booth CM, Tannock IF (2014) Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. Br J Cancer 110:551\u2013555","journal-title":"Br J Cancer"},{"key":"5484_CR19","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3389\/fped.2020.00048","volume":"8","author":"S Martin Ramos","year":"2020","unstructured":"Martin Ramos S, Gil-Calvo M, Roldan V, Castellano Martinez A, Santos F (2020) Positive response to one-year treatment with burosumab in pediatric patients with X-linked hypophosphatemia. Front Pediatr 8:48","journal-title":"Front Pediatr"},{"key":"5484_CR20","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1210\/jc.2003-030036","volume":"88","author":"O Makitie","year":"2003","unstructured":"Makitie O, Doria A, Kooh SW, Cole WG, Daneman A, Sochett E (2003) Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab 88:3591\u20133597","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-022-05484-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-022-05484-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-022-05484-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T11:12:24Z","timestamp":1663672344000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-022-05484-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,24]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["5484"],"URL":"https:\/\/doi.org\/10.1007\/s00467-022-05484-7","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,24]]},"assertion":[{"value":"4 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Study approved by the University of Wisconsin-Madison Health Sciences Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Waiver of informed consent granted by IRB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Neil Paloian is a member of the speaker\u2019s bureau of Ultragenyx pharmaceuticals. Robert D. Steiner reports equity interest in and consulting fees from Acer Therapeutics and PTC Therapeutics. He also reports leading an investigator-initiated observational research study funded by Alexion via contract with Marshfield Clinic Health System, and consulting fees from Alexion, Best Doctors, E-Scape Bio, Health Advances, Precision for Value, and Travere, and honoraria from Medscape\/WebMD and The France Foundation as well as employment with Prevention Genetics. The other authors have no relevant conflicts of interest or financial or proprietary interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}